TNFRSF4 and ovarian cancer: To improve the therapeutic outcome for ovarian cancer and other advanced malignancies, novel combinations of blocking antibodies targeting PD-L1, PD-1, and CTLA-4, with or without chemotherapeutics or immune-stimulating antibodies targeting 4-1BB or OX-40, are currently being clinically evaluated (ClinicalTrials.gov Identifier: NCT02608684, NCT03249142, NCT02554812).